SCHEMBL717947

SCHEMBL717947

ClC(c1cc2ccccc2o1)C1CCCCC1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 4/20 0.44
NPC1 O15118 4/20 0.44
MAOB P27338 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.41
KDM4E B2RXH2 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP2C19 P33261 1/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
BCHE P06276 2/20 0.40
ACHE P22303 2/20 0.40
CHRNB2 P17787 1/20 0.39
CHRNA4 P43681 1/20 0.39
CYP2D6 P10635 1/20 0.38
HIF1A Q16665 1/20 0.38
POLB P06746 2/20 0.38
ADRA2A P08913 1/20 0.38
ALDH1A1 P00352 1/20 0.37
HPGD P15428 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL717243 0.81 RAB9A (0.48) RAB9ANPC1MAOBSMN1; SMN2KDM4E
SCHEMBL719410 0.77 KDM4E (0.47) RAB9ANPC1KDM4ECYP1A2MEN1
SCHEMBL28045336 0.73 CYP2D6 (0.49) RAB9ANPC1MAOBSMN1; SMN2KDM4E
SCHEMBL719017 0.73 ALDH1A1 (0.51) RAB9ANPC1SMN1; SMN2KDM4ECYP1A2
SCHEMBL9170689 0.69 ACHE (0.70) RAB9ANPC1MAOBSMN1; SMN2KDM4E
SCHEMBL162882 0.69 NPC1 (0.52) RAB9ANPC1MAOBSMN1; SMN2KDM4E
SCHEMBL716824 0.68 NPC1 (0.48) RAB9ANPC1SMN1; SMN2KDM4ECYP2C19
SCHEMBL11754971 0.67 IDO1 (0.53) KDM4EMEN1KMT2AL3MBTL1CHRM2
SCHEMBL8893071 0.67 RAB9A (0.42) RAB9ANPC1MAOBSMN1; SMN2KDM4E
SCHEMBL28872300 0.67 ACHE (0.72) RAB9ANPC1MAOBSMN1; SMN2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8436043-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-05-07 US disclosed
US-20120270865-A2 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-10-25 US disclosed
US-20120053173-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-03-01 US disclosed
EP-2251326-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2010-11-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053173-A1 HETEROCYCLIC COMPOUND SLC5A2, SLC5A1, IAPP RAB9A 2454/4885NPC1 902/4885MAOB 2146/4885
US-20120270865-A2 HETEROCYCLIC COMPOUND SLC5A2, SLC5A1, IAPP RAB9A 2454/4885NPC1 902/4885MAOB 2146/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.